Discovering Treatment of Triple Negative Breast Cancer

Treating cancer remains a huge scientific challenge despite significant progress in the last decades. Treatment options for many cancer types are very limited and is some cases no effective treatments are available resulting in poor prognosis for these patients. In this seminar, I will briefly summarise why cancer is so difficult to treat. I will then describe a drug discovery project that has been going on at The Institute of Cancer Research. The aim of this project was to discover small molecule inhibitors of the mitotic kinase MPS1 as a new treatment for triple negative breast cancer (TNBC). TNBC is significant fraction of all breast cancers. It is characterised by a significantly worse prognosis than other breast cancers types and remains an area of unmet medical need. I will give an over of the MPS1 project from its inception to the discovery of our clinical candidate BOS172722 that is currently undergoing phase I clinical trials. A particular emphasis will be on the medicinal chemistry aspects of the project conducted in my research team.

CPS Members: Free of charge
Students: Purchase CPS membership on the door at £7.50 or £10 with a colour changing mug (valid for your entire degree)
Public: £2.

Please meet in the Nyholm Room of Christopher Ingold Building from 17:45 for Tea, Coffee and Doughnuts.
The talk will take place in the Ramsay LT at 18:15.
Join us after the talk for Wine, Cheese and Pizza!